Efficacy and Safety of Nanoadministration in the Treatment of Non-Small-Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta-Analysis

Abstract

Purpose. The purpose of this study was to evaluate the efficacy and safety of a nanodrug delivery regimen compared with conventional drug administration for the treatment of lung cancer. Materials and Methods. Studies were retrieved through PubMed, Web of Science, and ScienceDirect. Primary and secondary outcome measures, including overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events, were extracted from the retrieved literature and systematically evaluated. Results. Six trials, including 4806 advanced non-small-cell lung cancer patients, were included in this study. Compared with conventional drug administration in the treatment of lung cancer, the nanodrug delivery regimen improved the ORR (risk ratio = 1.43, 95% confidence interval (CI) = 1.25–1.63, p ≤ 0.001 ), prolonged PFS (hazard ratio (HR) = 0.83, 95% CI = 0.76–0.92, p ≤ 0.001 ), and obtained superior OS (HR = 0.91, 95% CI = 0.83–0.99, p ≤ 0.001 ). Regarding safety, the incidence of neutropenia, alopecia, sensory neuropathy, myalgia, and arthralgia was lower in the nanoadministration group, but the risk of thrombocytopenia, anaemia, and nausea was increased. Conclusion. Nanodrug administration is safe and effective in patients with non-small-cell lung cancer to some extent.

A novel defined necroptosis-related lncRNAs signature for predicting the prognosis of non-small cell lung cancer

“…Non-small cell lung cancer (NSCLC) is the most frequent pathological type representing 85% of all lung cancers, with over 4000 new diagnosed cases every year and a 5-year survival rate of approximately 15% (2). Due to the typical concealed characteristic of genesis and development of lung tumors, many NSCLC patients receive their cancer diagnoses at the middle and late stages and miss the opportunity for surgery (3). Statistics from the National Lung Cancer Center in 2016 illustrate that lung cancer is currently the principal cause of morbidity and mortality among malignancies in China.…”